{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+Product+A&page=2",
    "query": {
      "intervention": "Test Product A",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+Product+A&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T10:11:27.165Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02810418",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "LMB-100",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Mesothelin Expression",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2016-08-03",
      "completion_date": "2021-06-22",
      "has_results": true,
      "last_update_posted_date": "2022-03-15",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02810418"
    },
    {
      "nct_id": "NCT05024097",
      "title": "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Etrumadenant (AB928)",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "FOLFOX regimen",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab (AB122)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 43,
      "start_date": "2022-03-31",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 3,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05024097"
    },
    {
      "nct_id": "NCT02990013",
      "title": "AvenovaTM as a Sterile Skin Preparation Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cleaning Product Causing Toxic Effect"
      ],
      "interventions": [
        {
          "name": "Avenova",
          "type": "DEVICE"
        },
        {
          "name": "Povidone-iodine 5% solution",
          "type": "DRUG"
        },
        {
          "name": "4% chlorhexidine",
          "type": "DRUG"
        },
        {
          "name": "Isopropyl alcohol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2018-12-01",
      "completion_date": "2019-12-20",
      "has_results": false,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02990013"
    },
    {
      "nct_id": "NCT00365131",
      "title": "A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gaucher Disease Type I",
        "Cerebroside Lipidosis Syndrome",
        "Clucocerebrosidase Deficiency Disease",
        "Glucosylceramide Beta-Glucosidase Deficiency Disease",
        "Gaucher Disease, Non-Neuronopathic Form"
      ],
      "interventions": [
        {
          "name": "Cerezyme (imiglucerase for injection)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "10 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "1997-12",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2015-03-05",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 1,
      "location_summary": "Coral Springs, Florida",
      "locations": [
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00365131"
    },
    {
      "nct_id": "NCT03378102",
      "title": "Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "IFN-gamma-secreting HAdV antigen specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mari Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Months and older"
      },
      "enrollment_count": 20,
      "start_date": "2019-01-04",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03378102"
    },
    {
      "nct_id": "NCT06305637",
      "title": "A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tinea Versicolor"
      ],
      "interventions": [
        {
          "name": "Ketoconazole Shampoo, 2%",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole Shampoo, 2% (Reference Standard)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 430,
      "start_date": "2023-12-04",
      "completion_date": "2024-02-10",
      "has_results": false,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305637"
    },
    {
      "nct_id": "NCT06964087",
      "title": "Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type I Diabetes"
      ],
      "interventions": [
        {
          "name": "OPT101",
          "type": "DRUG"
        },
        {
          "name": "OPT101 Placebo to Match (PTM)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Op-T LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2026-04-10",
      "completion_date": "2028-08-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06964087"
    },
    {
      "nct_id": "NCT00667121",
      "title": "Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Depression",
        "Hot Flashes",
        "Psychosocial Effects of Cancer and Its Treatment"
      ],
      "interventions": [
        {
          "name": "citalopram hydrobromide",
          "type": "DRUG"
        },
        {
          "name": "escitalopram oxalate",
          "type": "DRUG"
        },
        {
          "name": "gabapentin",
          "type": "DRUG"
        },
        {
          "name": "sertraline hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "venlafaxine",
          "type": "DRUG"
        },
        {
          "name": "molecular genetic technique",
          "type": "GENETIC"
        },
        {
          "name": "high performance liquid chromatography",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 88,
      "start_date": "2011-03-16",
      "completion_date": "2014-05-27",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667121"
    },
    {
      "nct_id": "NCT06131021",
      "title": "Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Periodontitis",
        "Periodontal Diseases",
        "Periodontal Pocket"
      ],
      "interventions": [
        {
          "name": "Amoxicillin",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2024-04-25",
      "completion_date": "2026-04-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06131021"
    },
    {
      "nct_id": "NCT03880357",
      "title": "To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Scalp Psoriasis"
      ],
      "interventions": [
        {
          "name": "Betamethasone Scalp Suspension 0.064%;0.0005%",
          "type": "DRUG"
        },
        {
          "name": "Taclonex®",
          "type": "DRUG"
        },
        {
          "name": "Placebo topical suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 485,
      "start_date": "2018-10-22",
      "completion_date": "2019-03-15",
      "has_results": false,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-24T10:11:27.165Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03880357"
    }
  ]
}